课题基金 / 基金详情

PURINE NUCLEOSIDE PHOSPHORYLASE: NOVEL CHEMOTHER FOR LYMPHOMA & GRAFT REJECTION

PURINE NUCLEOSIDE PHOSPHORYLASE: NOVEL CHEMOTHER FOR LYMPHOMA & GRAFT REJECTION
嘌呤核苷磷酸化酶:淋巴瘤的新型化疗药物
批准号:
6120403
负责人:
STEVE ALMO
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-30 至 1999-08-31

项目摘要

项目成果

STEVE ALMO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Purine nuceloside phosphorylase (PNP) catalyzes the phosphorolysis of purine nucleosides to yield free purines and ?-1-ribose phosphate. A genetic defect in humans that results in the lack of PNP, results in a complete loss of T-cells, but no other effects. Thus PNP is an excellent target for the therapy of a number of T-cell specific pathologies including T-cell lymphomas and graft rejection. We have recently collected data to better than 2.0E on a complex between calf spleen PNP and a 20 pM transition state-inhibitor. Refinement is underway and currently reveals several of the strategies used by this enzyme to stabilize the transition state, which includes a conformational rearrangement. This structure represents one of the highest affinity enzyme-ligand complexes solved to date and will form the basis for future inhibitor development and mechanistic studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
STRUCT OF EVH1, TARGETING MODULE FOR SITE SPECIFIC ACTIN FILAMENT ASSEMBLY
PURINE NUCLEOSIDE PHOSPHORYLASE & NEW CHEMOTHERAPIES FOR LYMPHOMA & GRAFT REJECT
SYNCHROTRON CRYSTALLOGRAPHY BEAMLINE X9A STRUCTURE FUNCTION STUDIES
ACTIVE SITE TARGETING OF PROTEIN TYROSINE PHOSPHATASES BY SYNCH CRYSTALLOGRAPHY
海外基金